MINNEAPOLIS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“RWD”), today announced a growth initiative supporting women’s health research. The company is seeing increasing business and new opportunities from Life Science innovators including leading pharmaceutical companies requiring RWD for women’s health programs and has already filled multiple orders.
“Clinical imaging is the gold standard diagnostic tool for evaluating a large number of women’s health issues,” said Aaron Green, OneMedNet President. “Importantly, we have one of the largest regulatory-grade, image-centric RWD databases available and Life Science organizations and ultimately patients are benefiting from access.”
Women’s health research utilizing RWD includes several cancer types, cardiac disease, osteoporosis, Alzheimer’s, as well as other disease states. OneMedNet’s women’s health initiative will include dedicated resources aimed at better understanding the needs and opportunities in this critical sector.
OneMedNet features over 235+ healthcare providers within the iRWD® network. All data remains local to provider sites allowing researchers to dive deeper and/or expand their analysis with a complete folder of de-identified data available. The in-house data curation team are all clinically certified and ensure that every aspect of a requested cohort specification is met to exact detail.
About OneMedNet Corporation
OneMedNet was the first company to trademark a RWD offering through its OneMedNet iRWD™ solution that utilizes AI to securely de-identify, search, and curate imaging data for the benefit of its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet integrates AI and other digital technologies into their existing development processes to enhance data anomaly detection, standardization, and quality checking at the pre-processing stage. AI offers OneMedNet’s partners and customers the ability to increase meaningful Real World Evidence output, decrease time to insights, and make the most of the available vast data sources.
The OneMedNet iRWD network consists of more than 200 healthcare systems and providers. Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. For more information, please visit www.onemednet.com.
Investor Contact
Shannon Devine
MZ Group North America
203-741-8811
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.05 |
Daily Change: | 0.08 8.79 |
Daily Volume: | 135,744 |
Market Cap: | US$29.390M |
December 02, 2024 September 26, 2024 July 26, 2024 June 14, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB